| 前收市價 | 26.90 |
| 開市 | 27.05 |
| 買盤 | 27.50 x 28400 |
| 賣出價 | 27.50 x 2100 |
| 今日波幅 | 26.97 - 27.58 |
| 52 週波幅 | 24.96 - 60.15 |
| 成交量 | |
| 平均成交量 | 4,773,188 |
| 市值 | 26.918B |
| Beta 值 (5 年，每月) | 0.97 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -2.99 |
| 業績公佈日 | 2024年5月14日 |
| 遠期股息及收益率 | 0.11 (0.41%) |
| 除息日 | 2024年4月29日 |
| 1 年預測目標價 | 34.80 |
ZacksRoche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
FortunePharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thrive
Bayer currently has more than twelve tiers between management and its customers in some departments, and the aim of CEO Bill Anderson is to reduce that to around five or six.
Fox BusinessHow Roundup lawsuits could give China an edge
Legal fees associated with Bayer's Roundup, a weed-killing product used by farmers and gardeners who want to protect their crops or yards, have cost the company significantly.
